Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.40
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.50
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0801
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2644
    +0.0022 (+0.17%)
     
  • USD/JPY

    151.2330
    -0.1390 (-0.09%)
     
  • Bitcoin USD

    70,414.46
    -363.67 (-0.51%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Earnings Review and Free Research Report: Envision Healthcare Earnings Beat Analysts’ Estimates

Research Desk Line-up: AdCare Health Systems Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 25, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Envision Healthcare Corp. (NYSE: EVHC), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=EVHC, following the Company's release of its Q2 FY17 results on August 07, 2017. The Company reported a 251.3% increase in net revenues. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Long-Term Care Facilities industry. Pro-TD has currently selected AdCare Health Systems, Inc. (NYSE American: ADK) for due-diligence and potential coverage as the Company reported on August 14, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on AdCare Health Systems when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on EVHC; also brushing on ADK. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=EVHC

http://protraderdaily.com/optin/?symbol=ADK

Earnings Reviewed

The second quarter of FY17 saw Envision Healthcare generate revenues of $3.02 billion and net revenues of $1.95 billion compared to $859.8 million and $758.5 million in revenues and net revenues, respectively, in Q2 FY16; registering a growth of 251.3% y-o-y in revenues and 156.7% y-o-y in net revenues.

Net earnings attributable to Envision Healthcare's common stockholders were $54.1million in Q2 FY17 compared to $43.8 million in Q2 of FY16; a growth of 23.5% y-o-y.

Envision Healthcare reported net earnings from continued operations of $0.43 per share (EPS) for the second quarter of the current fiscal year compared to $0.82 in the corresponding quarter of the last fiscal year, and adjusted net earnings from continued operations was $0.85 per diluted share in Q2 FY17 against $1.10 in Q2 FY16.

The Company's EBITDA was $215.7 million for Q2 FY17 compared to $141.4 million for Q2 FY16, and adjusted EBITDA was $253.8 million in Q2 FY17 against $149.2 million in the same period of the last fiscal year.

The Company beat Wall Street's adjusted EPS estimates of $0.75 for the second quarter of the current fiscal year, but missed net revenues estimates of $1.96 billion.

Segment Information

Envision Healthcare reports two operating segments as continuing operations - Physician Services and Ambulatory Services.

Physician Services - This segment generated revenues of $1.63 billion in Q2 FY17 compared to $438.7 million in Q2 FY16; a growth of 271.2%y-o-y. The adjusted EBITDA and the adjusted EBITDA margin for the segment in Q2 2017 were $193.3 million and 11.9% respectively, against $87.5 million and 19.9%, respectively, in same quarter of the last fiscal year.

Ambulatory Services - This segment generated net revenues of $318.5 million in Q2 FY17 compared to $319.8 in Q2 FY16. Adjusted EBITDA and adjusted EBITDA margin in the segment were $60.5 million and 19%, respectively, for Q2 FY17 compared to $61.7 million and 19.3%, respectively, in Q2 FY16.

Cash Matters

Envision Healthcare generated $280.6 million in net cash flows from operating activities in Q2 FY17 compared to $113.3 million in the same period of the last fiscal year.

The Company used $480.9 million in investing activities for Q2 FY17 compared to an expenditure of $307.2 million in Q2 FY16.

Net cash flows generated by the Company from its financing activities were $421.9 million in Q2 FY17 versus $182.2 million in Q2 FY16.

The Company reported an increase in cash and cash equivalents in Q2 FY17 to the tune of $221.6 million while it had reported a decrease of $11.7 million in the same quarter for the last fiscal year.

The cash and cash equivalents at the end of Q2 FY17 available with the Company was $441.3 million compared to $ 74.1 million at the end of the same quarter in the last fiscal year.

Outlook

Envision healthcare revised its 2017 guidance, anticipating net revenues of $7.75 billion to $8.00 billion and adjusted EBITDA of $1.02 billion to $1.04 billion. The Company reduced the top-end of its most recent adjusted EBITDA guidance by $26 million primarily due to lower anticipated emergency medicine volumes than had been previously forecasted. The Company also expects adjusted EPS for 2017 to be in the range of $3.35 to $3.45.

For Q3 of the current fiscal year, Envision Healthcare expects to generate adjusted EBITDA of $266 million to $278 million, and adjusted EPS of $0.87 to $0.93.

Stock Performance

On Thursday, August 24, 2017, Envision Healthcare's stock closed the trading session at $50.82, slightly down 0.10% from its previous closing price of $50.87. A total volume of 1.11 million shares were exchanged during the session. The stock currently has a market cap of $6.10 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

Advertisement